Introduction
============

Chronic liver disease (CLD) is known to cause significant morbidity and mortality, typically due to a number of complications that include ascites, hepatic encephalopathy, variceal hemorrhage and hepatorenal syndrome \[[@B1],[@B2]\]. CLD negatively impacts health-related quality of life (HRQL) \[[@B3]-[@B6]\] with patients suffering from fatigue, loss of self-esteem, an inability to function at work, anxiety, depression and other emotional problems that profoundly decrease their quality of life and well-being \[[@B7]-[@B13]\]. Although recent research shows that HRQOL scores are independent prognostic factors for overall survival in patients with unresectable hepatocellular carcinoma (HCC) and can predict survival in liver transplant candidates \[[@B14]-[@B17]\], the relationship between HRQOL and survival in patients with CLD remains unclear. Therefore, the aim of this study was to examine whether scores from the Short Form 36 (SF-36) health survey are able to predict survival in Chinese patients with CLD.

Methods
=======

Ethics
------

The study received ethics approval from the Ethics Board of Beijing Chao-Yang Hospital, Capital Medical University and all participants gave written informed consent.

Patient selection
-----------------

Between September 2009 and September 2011, eligible patients with CLD, aged 18 to 80 years from the Digestive Department of Beijing Chao-Yang Hospital, Capital Medical University were approached to participate in the study. Patients with other chronic active medical diseases (such as congestive heart failure, chronic obstructive pulmonary disease), psychiatric conditions, malignancy, liver transplantation and those unable to communicate or who declined to participate were excluded. Patients with hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) infection or who received interferon therapy in the previous 3 months were also excluded. The healthy controls consisted of individuals without chronic disease, aged 18 to 80 years, male or female and who regularly undertook health screening in our hospital's health examination center. Healthy controls were used to exclude the influence of unpredictable events, social and environmental factors.

Each patient had an established diagnosis confirmed by a Hepatologist. The diagnosis of chronic HBV infection was based on the presence of hepatitis B surface antigen for more than six months, elevated serum alanine aminotransferase levels, with or without HBV DNA as detected by the hybridization method \[[@B18]\]. The diagnosis of chronic HCV infection was based on a positive hepatitis C antibody (ELISA II analysis), elevated serum alanine aminotransferase levels, with or without HCV RNA as detected by polymerase chain reaction \[[@B19]\]. The diagnosis of primary biliary cirrhosis was based on a positive antimitochondrial antibody and elevated liver enzymes with or without liver biopsy \[[@B20]\]. Alcohol was deemed the etiology of chronic liver disease if daily alcohol consumption was greater than 40 g for at least 10 years with elevated γ-glutamyl transferase and exclusion of other liver diseases \[[@B21]\]. The diagnosis of autoimmune hepatitis was based on simplified diagnostic criterion \[[@B22]\]. The diagnosis of liver cirrhosis was based on clinical, biochemical, serologic, ultrasonographic and radiographic parameters.

Data collection
---------------

On admission, patients gave written informed consent and completed the self-administered HRQOL questionnaire. The Medical Outcomes Study of Short Form36 (SF-36 v2 Chinese version) is a widely used and validated generic HRQOL questionnaire. Extensive demographic and clinical data were collected on admission and marital status was dichotomized into single and paired; single was extended to include unmarried persons, divorced or deceased couples.

Laboratory data included alanine and aspartate aminotransferases, alkaline phosphatase, γ-glutamyl transferase, total bilirubin, serum albumin, serum creatine, prothrombin time, serum potassium and sodium, hemoglobin, white blood cell and platelet counts (DADE Dimension Rx1 full-automatic biochemical analyzer).

HRQOL survey
------------

The SF-36 v2 Chinese Version (from Quality Metric Incorporated) consists of 36 items divided into eight domains that are aggregated into two summary scores, a mental component summary (MCS) and a physical component summary (PCS). These domains range from reflecting predominantly physical wellbeing, that include physical function (PF), the ability to perform expected physical roles (RP), the degree of bodily pain (BP) and overall sense of general health (GH) to those reflecting predominantly social and emotional well-being that include overall sense of vitality (VT), ability to function in social roles (SF), ability to perform expected emotional and social roles (RE) and overall sense of mental health (MH) \[[@B23]-[@B25]\].

Mortality assessment
--------------------

We followed all participants longitudinally and terminated the follow-up at the time of the patient's death or March 1st, 2013, whichever occurred first.

Comparison groups
-----------------

After the follow-up period, patients were divided into survival and deceased groups.

Statistical methods
-------------------

Categorical data were described as the number and continuous data as mean ± SE. Data were analyzed using independent sampled *t* test, one-way analysis of variance (ANOVA) or Chi-square test. Univariate Cox Proportional Hazard Regression analysis was conducted for PCS, MCS, demographic and clinical variables. Variables with a p value \<0.1 in univariate Cox Proportional Hazard Regression analysis were entered into multivariate Cox Proportional Hazard Regression analysis. Survival curves were estimated with the Kaplan-Meier method across the quartiles of PCS and MCS scores. A p value \<0.05 was considered as statistically significant. All data were analyzed with SAS 9.1.

Results
=======

Demographic and clinical data of respondents
--------------------------------------------

A total of 415 Chinese patients with CLD and 86 healthy controls were enrolled and 18 months of follow-up was completed. A total of 50 patients died and two patients were treated with liver transplantation, one in our hospital and one in a different hospital. Both patients died within one month and were therefore excluded from the analysis. The duration of follow-up for surviving and deceased patients was 30.7 ± 10.0 months and 12.1 ± 5.8 months respectively. A further 22 patients were lost to follow up and were also excluded from the analysis. There were no significant difference between the groups for health control and CLD, on age, gender, marital status or educational level (Table [1](#T1){ref-type="table"}).

###### 

Demographic data of different groups

  **Items**                              **Healthy control**   **Chronic liver disease**   **Independent sample*t*test or Chi-square**  
  ------------------------------------- --------------------- --------------------------- --------------------------------------------- ----
  Age (mean ± SE, yr)                        53.1 ± 13.1              54.2 ± 13.4                          *P* = 0.441                  
  Male/Female (*n*)                          51/35 59/41             243/172 58/42                         *P* = 0.898                  
  Paired/Single (*n*)                         84/2 98/2               396/19 95/5                          *P* = 0.343                  
  Educational level (*n*)                                                                                  *P* = 0.184                  
  Primary school                                10 11                    47 11                                                          
  Middle school                                 54 63                   273 66                                                          
  College or University                         18 21                    90 22                                                          
  College above                                  4 5                      5 1                                                           
  Etiologies of chronic liver disease            --               No Cirrhosis *n* %                     Cirrhosis *n* %                 --
  AIH (*n*)                                      --                      16 4                                 18 5                       --
  ALD (*n*)                                      --                      62 15                                54 13                      --
  CHB (*n*)                                      --                      54 13                                64 15                       
  CHC (*n*)                                      --                      28 7                                 36 9                       --
  PBC (*n*)                                      --                      34 8                                 35 8                       --
  Unknown (*n*)                                  --                       --                                  14 3                       --
  Present ascites                                --                       --                                 158 38                      --
  Present varices                                --                       --                                 196 47                      --
  Present bleeding                               --                       --                                  84 20                      --

*AIH* Autoimmune Hepatitis, *ALD* Alcoholic Liver Disease, *CHB* Chronic Hepatitis B, *CHC* Chronic Hepatitis C, *PBC* primary biliary cirrhosis.

Quality of life and clinical data of respondents
------------------------------------------------

All scores for SF-36 were significantly lower in deceased patients compared with surviving patients with CLD and healthy controls (Table [2](#T2){ref-type="table"}). Laboratory results from deceased patients showed significantly lower levels of albumin, hemoglobin, platelet count, serum potassium and serum sodium and significantly higher levels of total bilirubin, prothrombin time, blood urea nitrogen and serum creatinine.

###### 

HRQOL and clinical data of different groups (mean ± SE)

  **Items**               **Healthy control**   **Chronic liver disease**     **ANOVA**    
  ---------------------- --------------------- --------------------------- --------------- --------------
  Physical function           93.2 ± 6.4               86.6 ± 15.4           70.1 ± 29.9    *P* \< 0.001
  Physical roles              88.8 ± 15.6              80.5 ± 19.3           63.0 ± 32.6    *P* \< 0.001
  Bodily pain                 85.1 ± 15.1              87.3 ± 14.2           72.9 ± 26.2    *P* \< 0.001
  General health              75.3 ± 18.1              56.3 ± 21.3           44.9 ± 28.7    *P* \< 0.001
  Vitality                    83.5 ± 12.0              76.1 ± 10.7           42.7 ± 21.9    *P* \< 0.001
  Social roles                94.1 ± 10.6              81.0 ± 20.0           39.5 ± 21.0    *P* \< 0.001
  Emotional roles             92.9 ± 10.7              89.6 ± 13.4           54.4 ± 26.3    *P* \< 0.001
  Mental health               87.9 ± 25.0              79.3 ± 11.0           52.2 ± 23.4    *P* \< 0.001
  PCS                         54.1 ± 5.2               48.9 ± 7.7            33.5 ± 8.2     *P* \< 0.001
  MCS                         56.6 ± 8.2               53.0 ± 5.6            37.1 ± 12.1    *P* \< 0.001
  Laboratory data                                                                                 
  Albumin (g/L)               37.0 ± 2.7               35.3 ± 7.4            24.5 ± 4.8     *P* \< 0.001
  ALT (U/L)                   23.0 ± 10.4              56.3 ± 62.8           37.8 ± 31.7    *P* = 0.001
  AST (U/L)                   23.4 ± 12.7              63.3 ± 69.5           82.7 ± 69.4    *P* \< 0.001
  GGT (U/L)                   51.8 ± 58.0             102.8 ± 146.3         123.9 ± 216.9   *P* = 0.088
  ALP (U/L)                  105.6 ± 72.0             126.8 ± 94.9          140.7 ± 128.0   *P* = 0.267
  TBIL (umol/L)                9.4 ± 3.9               26.8 ± 35.7           81.4 ± 77.1    *P* \< 0.001
  BUN (umol/L)                 5.0 ± 0.9                5.4 ± 2.8             9.9 ± 7.4     *P* \< 0.001
  Cr (umol/L)                 68.8 ± 14.7              77.2 ± 26.0          109.1 ± 65.5    *P* \< 0.001
  Prothrombin time (s)        10.5 ± 0.5               13.3 ± 2.8            18.3 ± 5.7     *P* \< 0.001
  WBC (10^9^/L)                6.0 ± 1.4                4.7 ± 2.0             5.6 ± 4.7     *P* \< 0.001
  Hemoglobin (g/L)           136.0 ± 19.8             118.7 ± 25.4           90.6 ± 20.7    *P* \< 0.001
  Platelet (10^9^/L)         210.4 ± 35.0             131.1 ± 75.3           77.3 ± 44.5    *P* \< 0.001
  K (mmol/L)                   4.0 ± 0.3                4.0 ± 0.4             3.8 ± 0.7     *P* = 0.041
  Na (mmol/L)                 140.2 ± 3.5              140.8 ± 7.9           135.7 ± 6.9    *P* \< 0.001

*PCS* physical component summary, *MCS* mental component summary, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *ALP* alkaline phosphatase, *GGT* γ-glutamyl transferase, *TBIL* total bilirubin, *Cr* serum creatine, *BUN* blood urea nitrogen, *K* serum potassium, *Na* serum sodium, *WBC* white blood cell.

Cox proportional hazard regression
----------------------------------

All variables related to survival with a p value of \<0.1 in the univariate analyses were subjected to multivariate analyses. PCS scores, MCS scores and the presence of ascites were significantly associated with survival (Table [3](#T3){ref-type="table"}). For a one point increase of PCS, the risk of death was reduced by 0.099. For a point increase of MCS, the risk of death reduced by 0.124. The presence of ascites increased the risk of death by 7.432. Model Fit Statistics (AIC) for multivariate was 369.08 (p \< 0.001).

###### 

Results of Cox regression analyses

  **Variables**           **Univariate**       **Multivariate**                         
  ------------------- ----------------------- ------------------ ---------------------- -------------
  Physical function    0.971 (0.961--0.981)      *P* \<0.001               --                --
  Physical roles       0.973 (0.963--0.983)      *P* \<0.001               --                --
  Bodily pain          0.964 (0.952--0.977)      *P* \<0.001               --                --
  General health       0.979 (0.967--0.991)      *P* \<0.001               --                --
  Vitality             0.911 (0.898--0.925)       *P* =0.001               --                --
  Social roles         0.934 (0.921--0.947)      *P* \<0.001               --                --
  Emotional roles      0.935 (0.924--0.945)      *P* \<0.001               --                --
  Mental health        0.925 (0.913--0.937)      *P* \<0.001               --                --
  PCS                  0.852 (0.826--0.880)      *P* \<0.001      0.901 (0.867--0.935)   *P* \<0.001
  MCS                  0.856 (0.834--0.878)      *P* \<0.001      0.876 (0.848--0.905)   *P* \<0.001
  Age                  1.059 (1.034--1.084)      *P* \<0.001               --                --
  Etiology             1.118 (0.967--1.294)       *P* =0.131               --                --
  MELD                 1.121 (1.074--1.170)      *P* \<0.001               --                --
  Ascites              89.883 (12.40--651.0)     *P* \<0.001      8.432(1.117--63.63)    *P =* 0.038
  ALT                  0.992 (0.983--1.000)      *P* = 0.056               --                --
  AST                  1.003 (1.000--1.006)      *P* = 0.073               --                --
  PT                   1.197 (1.152--1.243)      *P* \<0.001               --                --
  TBIL                 1.011 (1.008--1.014)      *P* \<0.001               --                --
  WBC                  1.132 (1.045--1.227)       *P* =0.002               --                --
  HGB                  0.964 (0.954--0.974)      *P* \<0.001               --                --
  PLT                  0.985 (0.979--0.992)      *P* \<0.001               --                --
  Albumin              0.803 (0.766--0.843)      *P* \<0.001               --                --
  Cr                   1.012 (1.008--1.015)      *P* \<0.001               --                --
  BUN                  1.132 (1.096--1.169)      *P* \<0.001               --                --
  K                    0.451 (0.243--0.837)       *P* =0.011               --                --
  Na                   0.979 (0.968--0.990)      *P* \<0.001               --                --

*PCS* physical component summary, *MCS* mental component summary, *MELD* model for end stage liver disease, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *PT* Prothrombin Time, *TBIL* total bilirubin, *Cr* serum creatine, *BUN* blood urea nitrogen, *K* serum potassium, *Na* serum sodium, *WBC* white blood cell. Etiology includes autoimmune Hepatitis, alcoholic Liver Disease, chronic Hepatitis B, chronic Hepatitis C, and primary biliary cirrhosis. Model Fit Statistics (AIC) score of multivariate is 369.08 and *P* \<0.001.

Kaplan-Meier analysis
---------------------

Survival was significantly different across the quartiles of PCS scores, MCS scores and with the presence of ascites (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Three points of quartile for PCS were 43.5, 50.6, 55.2, and for MCS were 48.9, 53.5, 57.4. Three points of quartile for PCS with the presence of ascites were 33.0, 40.8, 45.8, and for that of MCS were 43.3, 51.2, 55.8.

![**Kaplan-Meier analysis showing association between PCS scores and survival, log-rank*P*** **\< 0.001.**](1477-7525-11-131-1){#F1}

![Kaplan-Meier analysis showing association between MCS scores and survival, log-rank p \< 0.001.](1477-7525-11-131-2){#F2}

![Kaplan-Meier analysis showing association between PCS scores plus present ascites and survival, log-rank p \< 0.001.](1477-7525-11-131-3){#F3}

![Kaplan-Meier analysis showing association between MCS scores plus present ascites and survival, log-rank p \< 0.001.](1477-7525-11-131-4){#F4}

Discussion
==========

The results from this study show that deceased patients with CLD had a poor baseline quality of life and a poor clinical state compared with patients who survived. Baseline HRQOL scores were also much worse compared with healthy controls. Recent studies have shown that patients with CLD have substantially reduced HRQOL scores, however, the scores do not differ markedly according to the etiology of the disease. Increasing disease severity is also associated with a poor HRQOL, particularly for the physical component \[[@B3]-[@B5],[@B10]-[@B13]\]. With progression of liver dysfunction, patients with CLD suffer from fatigue, loss of self-esteem, an inability to function at work, anxiety, depression and other emotional problems that profoundly decrease their quality of life and well-being \[[@B23],[@B26]\]. Furthermore, patients with CLD suffer from complications that reduce their HRQOL, especially for the physical domain area and are less able to maintain daily work and life \[[@B23]-[@B30]\]. Our previous study also found that patients with CLD had impaired HRQOL and increasing severity of CLD was associated with a decreasing HRQOL score \[[@B31]\]. Old age, female gender, advanced stage of CLD, presence of ascites, hyperbilirubinemia and a prolonged prothrombin time were important factors in reducing HRQOL.

In this study, patients with higher PCS and MCS scores had a markedly increased survival rate. In a recent report, PCS but not MCS scores from the SF-36 predicted survival \[[@B16]\]. Another report showed that disease-specific HRQOL components, rather than PCS and MCS can be used to identify patients with advanced liver disease who are at high risk of short-term death \[[@B17]\]. There are several possible reasons for this discrepancy. Firstly, the intervention of liver transplantation can markedly improve HRQOL, especially the physical domains, however, in our study, patients only received medical treatment where liver transplantation would have been appropriate, but is limited by funding issues (15 cases per annum receive liver transplantation in our hospital). With progression of liver dysfunction, patients with cirrhosis suffer from fatigue, loss of self-esteem, inability to function at work, anxiety, depression and other emotional problems that profoundly decrease their quality of life and well-being \[[@B23],[@B26]\]. Our previous study showed reduced MCS scores with increasing severity of CLD \[[@B31]\]. Secondly, most patients in our study were relatively stable with a lower mean score of MELD (mean = 7.7) and only 12% died during the follow-up period of 18 months. Therefore, both PCS and MCS were significantly associated with survival.

We found that the presence of ascites was significantly associated with reduced survival, a finding not documented in previous studies even though ascites is the most common complication of advanced CLD. The presence of ascites is regarded as a serious manifestation of advanced CLD and reflects the onset of liver decompensation with an increased mortality (15% in the first year and 44% in the 5 years after diagnosis). Ascites usually becomes refractory to diuretic control with progression of CLD, where survival rates approach 50% at one year \[[@B32]\].

HRQOL measures, such as the SF-36, a generic questionnaire, is used to measure HRQOL in the general population and in patients with chronic diseases including CLD. Many research centers have used HRQOL to compare CLD patients with healthy controls and have generally reported impairment of HRQOL. Additionally, measurement of HRQOL can facilitate integration of biomedical and psychosocial models of health. This integrated approach in the study of patients with CLD will capture the impact of these diseases on patient's health and well-being \[[@B23]-[@B30]\]. Several recent studies have established that better HRQOL is an independent predictor of survival in many chronic diseases such as end-stage renal disease, congestive heart failure, type 2 diabetes and various cancers \[[@B33]-[@B36]\]. Further studies also suggest that HRQOL could be used to predict survival of patients with advanced CLD \[[@B14],[@B16],[@B17]\]. Therefore, measurement of HRQOL might compliment objective measures of disease severity to not only accurately and comprehensively assess health status, but also to better stratify risk in patients with CLD.

Our study has a number of limitations. All subjects were recruited from one hospital in one city. Our hospital is a public general affiliated hospital of Capital Medical University and three levels of first-class or China's most senior hospital in Beijing. Our department has 42 beds including an endoscopy suite. We serve over 150,000 outpatients per year, over 1,800 in-patients per year and over 20000 endoscopies per year that might introduce selection bias. Our sample consisted mostly of patients with health insurance who have better access to healthcare. Therefore, our patient sample excludes patients without health insurance with limited access to care. Our study included patients with CLD with different etiologies and severity. We are addressing these issues in ongoing studies by assessing a larger group of patients in multiple centers.

Summary
=======

HRQOL was associated with survival in patients with CLD. PCS and MCS scores were predictors of survival.
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